Make earnings with no risk
Automated AI-driven system makes the trades, you earn the money
Join now

Asia-Pacific Stocks Show Mixed Performance


The Asia-Pacific stock markets exhibited a mixed trend on Thursday, August 17th, with some countries experiencing declines while others saw gains.

Japan and Hong Kong Markets

In Japan, the Nikkei 225 Index (NIK) saw a decline of 0.4%, settling at 31,626.00. Among the index constituents, Rakuten Group (4755), an e-commerce company, experienced the largest drop, with shares declining by 4.4%. Similarly, digital marketing services firm CyberAgent (4751) and optical instruments company Hoya Corp (7741) witnessed a decline of 3.9% and 3.6% respectively. On the other hand, commercial banking company Chiba Bank (8331) observed the largest increase in shares as it gained 3.7%. Additionally, wires/cables firm Fujikura Ltd (5803) and passenger cars company Subaru (7270) saw growth of 2.7% and 2.2% respectively.

Meanwhile, in Hong Kong, the Hang Seng Index (HSI) remained relatively flat at 18,326.63. Real estate services/transactions company Country Garden Holdings (2007) experienced the largest decrease, with shares dropping by 7.2%. Pharmacy/drug store firms Alibaba Hlth Info Tech (241) and JD Health International (6618) also witnessed declines of 7.1% and 6.4% respectively. Conversely, alcoholic beverages/drinks company China Resources Beer Holdings (291) saw a significant increase of 4.3% in share prices. Sporting goods retailing firm Li Ning (2331) and brewing company Budweiser Brewing APAC (1876) also noted growth, with gains of 3.4% and 2.5% respectively.

Other Countries in the Region

In China, the Shanghai Composite Index (SHCOMP) increased by 0.4% to reach 3,163.74. Singapore’s FTSE Straits Times Index (STI) weakened by 0.4%, settling at 3,199.17. South Korean stocks, represented by the KOSPI Composite Index (180721), also experienced a decline of 0.2%, with the index reaching 2,519.85. Additionally, Australia’s S&P/ASX 200 Benchmark Index (XJO) witnessed a 0.7% decrease, settling at 7,146.00.

Pfizer and Flagship Pioneering Collaborate on New Medicine Development

Previous article Group Reports Strong Revenue Growth and Raises Outlook for 2023

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in News